---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003796"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-04T20:10:48+00:00"
generated_at: "2026-08-04T20:12:20.194844+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers

## Summary
- SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.
- Combined with prior MHC-I upregulation, data supports coordinated immune-sensitization across three key immune pathways.
- Findings observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.
- Company advancing SIL204 into Phase 2/3; first clinical trial site initiated at Tel Aviv Sourasky Medical Center in July 2026.
- Management believes data supports combining SIL204 with anti-PD-(L)1 checkpoint inhibitors.

## SEC filing metadata
- accession: 0001178913-26-003796
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-04T20:10:48+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/0001178913-26-003796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/zk2635818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003796
- JSON: https://secwatch.observer/filing/0001178913-26-003796.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.